<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592409</url>
  </required_header>
  <id_info>
    <org_study_id>125/2011</org_study_id>
    <nct_id>NCT01592409</nct_id>
  </id_info>
  <brief_title>Cannabis Effects on Driving-related Skills of Young Drivers</brief_title>
  <official_title>Acute and Residual Effects of Cannabis on Young Drivers' Performance of Driving-related Skills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Motor vehicle collisions are the leading cause of death for young people. The investigators
      have recently found that driving after using cannabis is more common among young Canadian
      drivers than driving after drinking. While this observation raises concerns, the effects of
      cannabis on driving-related skills in this age group are not well understood. As well,
      evidence suggests that residual effects of cannabis on driving-related skills may be observed
      up to 24 hours later. These residual effects may have important implications for the effects
      of cannabis use on collision risk, but little evidence on them in available. This study will
      examine the effects of a single dose of cannabis (marijuana) on driving-related skills
      immediately following consumption, 24 hours later, and 48 hours later. To date, the residual
      effect at 48 hours has not been examined. A total of 142 subjects aged 19 to 25 years old
      will be randomly assigned to smoke either a placebo or active cannabis cigarette (12.5% THC
      potency). Following an eligibility screening and practice session, participants will attend 3
      testing days; drug-administration, 24-hour follow-up and 48-hour follow-up. The effects of
      cannabis/placebo on performance of driving-related skills using a high-fidelity driving
      simulator will be assessed on each testing day. The effects of cannabis on mood, cognition,
      memory and complex reaction time will also be assessed. Identifying factors that affect the
      collision risks experienced by young drivers is a public health priority. While many young
      people believe that cannabis does not impair driving, some recent studies suggest that these
      may be very dangerous beliefs. This study will provide important information on how cannabis
      may affect the driving skills of young drivers, to inform efforts to understand and address
      cannabis-related collision in this age group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the prediction that residual effects of an acute dose of cannabis on
      driving-related skills will be observed in a group of young drivers 48 hours following a
      single dose of smoked cannabis, and will also examine the effects of an acute dose of
      cannabis on those skills using driving simulator technology.

      Study Objectives

        1. Examine the residual effects of a moderate dose of cannabis (12.5% THC) on driving
           simulator performance of young drivers. Simulated driving performance, tests of
           cognition, verbal memory, and mood will be measured concurrently with levels of
           cannabinoids in biological fluids at approximately 24 and 48 hours following acute drug
           exposure in male and female drivers aged 19 to 25. We will test the hypothesis that
           performance on a high-fidelity driving simulator task will be significantly impaired
           approximately 24 hours following a dose of cannabis in comparison to a placebo
           condition.

        2. Examine the acute effects of a moderate dose of cannabis (12.5% THC) on driving
           simulator performance of young drivers. Simulated driving performance, tests of
           cognition, verbal memory, and mood will be measured concurrently with levels of
           cannabinoids in biological fluids before and after drug administration. Cannabinoid
           levels in biological fluids will be measured over a 6 hour period following drug
           exposure. We will examine the relationship of cannabinoid levels to performance measures
           in this time frame.

        3. Explore the effects of driving history, driving attitudes, and individual difference
           measures (e.g., demographics, drug and alcohol use, etc.) on the acute and residual
           effects of cannabis on driving simulator performance of young drivers. Exploratory
           analyses will be undertaken to determine if the acute and residual effects of cannabis
           on the driving simulator task are influenced by these measures.

        4. Determine if a relationship exists between genetics and THC response. As an ancillary
           aim, blood samples may be collected for future research to determine if a relationship
           exists between genetic polymorphisms and pharmacokinetic and pharmacodynamic responses
           to cannabis.

      Study Design and Duration

      The study is a double-blind, placebo-controlled mixed-design study, including a randomized
      between-subjects comparison of the effects of smoked cannabis and both between- and
      within-subjects examination of its residual effects at 24 and 48 hours following one-time
      drug administration. Although a placebo condition is part of the study, this is not a
      treatment study.

      Initial contact with potential subjects will be made via telephone, and study personnel will
      conduct a telephone screen for eligibility. Upon eligibility confirmation by telephone,
      participants will be asked to attend CAMH for an eligibility assessment. The study will
      consist of 5 sessions for each subject (an eligibility assessment, a practice day, and three
      subsequent testing days). Participants will be asked not to use cannabis for 48 hours prior
      to attending the practice day (Session 2). Although Session 1 can be completed at any time
      prior to the remaining study sessions, Sessions 2 - 5 must be performed on consecutive days.

      In certain instances, the Qualified Investigator may ask a participant to return for
      re-screening, e.g. repeat of urine test or other assessments performed for eligibility
      assessment. Also, in case of unforeseen delays in scheduling study participation, the
      Qualified Investigator will determine if there is a need to ask a participant to repeat some
      assessments, e.g., physical examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychomotor Impairment (Driving)</measure>
    <time_frame>Approximate: at baseline (30 minutes before smoking), 30 minutes after smoking</time_frame>
    <description>The driving simulator will objectively measure driving behaviour during a number of pre-programmed driving scenarios. Zone/ Hazard performance measure: Mean Speed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Psychomotor Impairment</condition>
  <arm_group>
    <arm_group_label>Active cannabis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this condition, participants will receive a cigarette containing 12.5% active THC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>delta-9-tetrahydrocannabinol</intervention_name>
    <description>A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.</description>
    <arm_group_label>Active cannabis</arm_group_label>
    <other_name>cannabis sativa</other_name>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>cannabis sativa</other_name>
    <other_name>marijuana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 19 to 25

          -  Regular cannabis users (between one and four times per week)

          -  Held a valid class G or G2 Ontario driver's license (or equivalent from another
             jurisdiction) for at least 12 months.

          -  Willing to abstain from cannabis use for the duration of the study, and for 48 hours
             prior to Session 2.

          -  Provides written and informed consent

          -  Urine toxicology result positive for THC (indicating recent use of cannabis).

        Exclusion Criteria:

          -  Positive breathalyzer results for alcohol on any given study day.

          -  Is a regular user of medications that affect brain function (i.e., antidepressants,
             benzodiazepines, stimulants).

          -  Diagnosis of severe medical or psychiatric conditions.

          -  A first degree relative diagnosed with schizophrenia.

          -  Meets criteria for current or lifetime Substance Use Disorders (DSM-IV) with the
             exception of nicotine.

          -  Meets criteria for Cannabis Dependence (DSM-IV).

          -  Is pregnant, is trying to become pregnant, or is currently breastfeeding.

        Ongoing Exclusion Criteria:

          -  Upon eligibility assessment, toxicology results indicate that the participant has not
             used cannabis recently.

          -  Any toxicology screen after Session 2 - Practice Day indicating a psychoactive
             substance has been used other than cannabis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Mann, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Le Foll, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.camh.net/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital, fully affiliated with the University of Toronto, and a PAHO/WHO Collaborating Centre</description>
  </link>
  <reference>
    <citation>Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa, Canada: Canadian Cenre for Substance Abuse 2005</citation>
  </reference>
  <reference>
    <citation>Johnston LD, O'Malley PM, Backman JG, Schulenber JE. Monitoring the future: National results on adolescent drug use. Bethesda, MD.: National Institute on Drug Abuse 2009</citation>
  </reference>
  <reference>
    <citation>WHO - Programme on substance abuse. Cannabis: a health perspective and research agenda: World Health Organization 1997.</citation>
  </reference>
  <reference>
    <citation>Chipman ML, Macdonald S, Mann RE. Being &quot;at fault&quot; in traffic crashes: does alcohol, cannabis, cocaine, or polydrug abuse make a difference? Inj Prev. 2003 Dec;9(4):343-8.</citation>
    <PMID>14693897</PMID>
  </reference>
  <reference>
    <citation>Brault M, Dussault C, Bouchard J, Lemire AM. The contribution of alcohol and other drugs among fatally injured drivers in Quebec: final results. Société de l'assurance automobile du Quebec 2002. Available from: http://www.saaq.gouv.qc.ca/publications/dossiers_etudes/drogue_an.pdf</citation>
  </reference>
  <reference>
    <citation>Laumon B, Gadegbeku B, Martin JL, Biecheler MB; SAM Group. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005 Dec 10;331(7529):1371. Epub 2005 Dec 1. Erratum in: BMJ. 2006 Jun 3;332(7553):1298.</citation>
    <PMID>16321993</PMID>
  </reference>
  <reference>
    <citation>Siliquini R, Chiadò Piat S, Gianino MM, Renga G. Drivers involved in road traffic accidents in Piedmont Region: psychoactive substances consumption. J Prev Med Hyg. 2007 Dec;48(4):123-8.</citation>
    <PMID>18557306</PMID>
  </reference>
  <reference>
    <citation>Stoduto G, Vingilis E, Kapur BM, Sheu WJ, McLellan BA, Liban CB. Alcohol and drug use among motor vehicle collision victims admitted to a regional trauma unit: demographic, injury, and crash characteristics. Accid Anal Prev. 1993 Aug;25(4):411-20.</citation>
    <PMID>8357454</PMID>
  </reference>
  <reference>
    <citation>Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev. 2004 Mar;36(2):239-48.</citation>
    <PMID>14642878</PMID>
  </reference>
  <reference>
    <citation>Lacey JH, Kelley-Baker T, Furr-Holden D, Voas RB, Romano E, Ramirez A, et al. 2007 National roadside survey of alcohol and drug use by drivers: Drug results. Washington, DC: National Highway Traffic Safety Administration 2009.</citation>
  </reference>
  <reference>
    <citation>Blows S, Ivers RQ, Connor J, Ameratunga S, Woodward M, Norton R. Marijuana use and car crash injury. Addiction. 2005 May;100(5):605-11.</citation>
    <PMID>15847617</PMID>
  </reference>
  <reference>
    <citation>Asbridge M, Poulin C, Donato A. Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prev. 2005 Nov;37(6):1025-34. Epub 2005 Jun 29.</citation>
    <PMID>15992751</PMID>
  </reference>
  <reference>
    <citation>Adlaf EM, Mann RE, Paglia A. Drinking, cannabis use and driving among Ontario students. CMAJ. 2003 Mar 4;168(5):565-6.</citation>
    <PMID>12615749</PMID>
  </reference>
  <reference>
    <citation>Fischer B, Rodopoulos J, Rehm J, Ivsins A. Toking and driving: Characteristics of Canadian university students who drive after cannabis use - an exploratory pilot study. Drugs Ed Prev Policy 13:179-87, 2006</citation>
  </reference>
  <reference>
    <citation>O'Malley PM, Johnston LD. Drugs and driving by American high school seniors, 2001-2006. J Stud Alcohol Drugs. 2007 Nov;68(6):834-42.</citation>
    <PMID>17960301</PMID>
  </reference>
  <reference>
    <citation>McGuire F, Dawe M, Shield KD, Rehm J, Fishcher B. Driving under the influence of cannabis or alcohol in a cohort of high-frequency cannabis users: prevalence and reflections on current interventions. Canadian Journal of Criminology and Criminal Justice 53(2): 247-259, 2011</citation>
  </reference>
  <reference>
    <citation>Pope HG Jr, Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995 Apr;38(1):25-34. Review.</citation>
    <PMID>7648994</PMID>
  </reference>
  <reference>
    <citation>Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990 Nov;37(3):561-5.</citation>
    <PMID>1965045</PMID>
  </reference>
  <reference>
    <citation>Smiley A. Marijuana: On-road and driving simulator studies. Alcohol, Drugs, and Driving. 2:121-34, 1986</citation>
  </reference>
  <reference>
    <citation>Crancer A Jr, Dille JM, Delay JC, Wallace JE, Haykin MD. Comparison of the effects of marihuana and alcohol on simulated driving performance. Science. 1969 May 16;164(3881):851-4.</citation>
    <PMID>5767792</PMID>
  </reference>
  <reference>
    <citation>Cone EJ, Huestis MA. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit. 1993 Dec;15(6):527-32. Review.</citation>
    <PMID>8122288</PMID>
  </reference>
  <reference>
    <citation>Harder S, Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther. 1997 Apr;35(4):155-9.</citation>
    <PMID>9112136</PMID>
  </reference>
  <reference>
    <citation>McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction. 2008 Jul;103(7):1100-9. doi: 10.1111/j.1360-0443.2008.02230.x. Epub 2008 May 20. Review.</citation>
    <PMID>18494838</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>December 5, 2017</results_first_submitted>
  <results_first_submitted_qc>September 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2019</results_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Robert Mann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cannabis impaired driving</keyword>
  <keyword>driving simulation</keyword>
  <keyword>acute psychopharmacologic effects of cannabis</keyword>
  <keyword>residual effects of cannabis</keyword>
  <keyword>young drivers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Disorders</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was by media ads and research postings in Toronto.</recruitment_details>
      <pre_assignment_details>Screened over the telephone n=1024. Assessed for eligibility (n=178). Excluded: Not meeting inclusion criteria n=45, Declined to participate or lost interest n=32, Did not receive IP (did not return after practice session) n=2.
Pilots (received active cannabis, not randomized) n=5. Randomized n=94.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Cannabis</title>
          <description>In this condition, participants will receive a cigarette containing 12.5% active THC.
delta-9-tetrahydrocannabinol: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
Placebo: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant was excluded from analyses because they admitted to having tried to skew their data. They withdrew from the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Active Cannabis</title>
          <description>In this condition, participants will receive a cigarette containing 12.5% active THC.
delta-9-tetrahydrocannabinol: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
Placebo: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.22" spread="1.88"/>
                    <measurement group_id="B2" value="21.97" spread="2.24"/>
                    <measurement group_id="B3" value="22.14" spread="1.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Psychomotor Impairment (Driving)</title>
        <description>The driving simulator will objectively measure driving behaviour during a number of pre-programmed driving scenarios. Zone/ Hazard performance measure: Mean Speed.</description>
        <time_frame>Approximate: at baseline (30 minutes before smoking), 30 minutes after smoking</time_frame>
        <population>Zone/Hazard performance measure: Mean Speed (Change from drug-free baseline to 30 minutes after smoking cannabis in kilometres per hour (kph)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Cannabis</title>
            <description>In this condition, participants will receive a cigarette containing 12.5% active THC.
delta-9-tetrahydrocannabinol: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
Placebo: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).</description>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor Impairment (Driving)</title>
          <description>The driving simulator will objectively measure driving behaviour during a number of pre-programmed driving scenarios. Zone/ Hazard performance measure: Mean Speed.</description>
          <population>Zone/Hazard performance measure: Mean Speed (Change from drug-free baseline to 30 minutes after smoking cannabis in kilometres per hour (kph)</population>
          <units>change in kph</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="9.75"/>
                    <measurement group_id="O2" value="-1.54" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected from session 1 (eligibility assessment) to session 2 (practice) (approx. 3 months); from session 2 to 3 (approx. 24 hours), from session 3 to 4 (approx. 24 hours), session 4 to session 5 (approx. 24 hours).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Cannabis</title>
          <description>In this condition, participants will receive a cigarette containing 12.5% active THC.
delta-9-tetrahydrocannabinol: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
Placebo: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>rapid heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>earache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>simulation sickness</sub_title>
                <description>nausea/dizziness due to driving simulator</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>stomach/abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness/faintness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>difficulty falling asleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>nasal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>tiredness/fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>injury</sub_title>
                <description>sprained ankle, burn</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>muscle/bone/joint pain</sub_title>
                <description>arm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety/nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>genital discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <description>at site of blood draw</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>low blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>loss of consciousness</sub_title>
                <description>vasovagal episode</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study examined simulated driving behavior of young regular cannabis users (1 to 4 times per week) and the generalization to new or frequent cannabis users, older drivers, and to real-world driving is unclear.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert Mann, Senior Scientist</name_or_title>
      <organization>Centre for Addiction and Mental Health</organization>
      <phone>416-535-8501 ext 34496</phone>
      <email>robert.mann@camh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

